Could a Once-a-Year cholera shot be just as good?
NCT ID NCT07487077
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study in Nairobi, Kenya, is testing whether giving the oral cholera vaccine Euvichol-S at longer intervals (3 months or 12 months) works as well as the standard 2-week schedule. Over 1,000 healthy participants aged 1 year and older will be randomly assigned to one of three dosing schedules. The goal is to see if flexible timing can still protect against cholera, which could make vaccination campaigns easier in areas where outbreaks are common.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Euvichol-S oral cholera vaccine
- What this could lead to
- If successful, this could allow more flexible vaccination schedules, making it easier to protect communities against cholera in outbreak-prone areas.
- What could go wrong
- This is a Phase 4 trial, but it is still early for these specific dosing schedules. The results may not apply to other regions or populations, and the vaccine may not provide the same level of protection with longer intervals.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOLERA VACCINATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
KEMRI
RECRUITINGNairobi, Kenya
More trials for these conditions
Other studies related to the condition(s) this trial covers.